Stay updated with breaking news from Vyriad Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced that its...
ROCHESTER, Minn., Nov. 9, 2023 /PRNewswire/ — Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced that its abstract, In Vivo Generation of Functional CD19 CAR-T Cells Using a Serum-Stable CD3-Targeted Lentiviral Vector, has been selected for an oral presentation at the 65th American Society of Hematology Annual […]
Dublin, Aug. 02, 2023 (GLOBE NEWSWIRE) -- The "Bladder Cancer Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's...
Global Bladder Cancer Drugs Market Global Bladder Cancer Drugs Market Dublin, Aug. 02, 2023 (GLOBE NEWSWIRE) -- The "Bladder Cancer Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global bladder cancer drugs market is witnessing robust expansion, with a projected value of $2.66 billion in 2023, rising from $2.32 billion in 2022. This impressive growth is driven by a compound annual growth rate (CAGR) of 14.4%. The market is expected to continue it
/PRNewswire/ -- DelveInsight's Neuroendocrine Tumors Market Insights report includes a comprehensive understanding of current treatment practices,...